BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:18 PM
 | 
May 06, 2009
 |  BC Extra  |  Company News

FDA approves Avastin in glioblastoma

FDA granted accelerated approval of Avastin bevacizumab from Genentech Inc. for use in patients with previously treated glioblastoma multiforme (GBM). In March, an FDA...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >